NASDAQ:FMTX

Forma Therapeutics News Headlines

$25.99
+0.64 (+2.52 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$24.64
$26.21
50-Day Range
$22.86
$30.95
52-Week Range
$21.10
$56.33
Volume1.10 million shs
Average Volume420,924 shs
Market Capitalization$1.23 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Forma Therapeutics (NASDAQ FMTX) News Headlines Today

SourceHeadline
Forma Therapeutics (NASDAQ:FMTX) Price Target Cut to $54.00 by Analysts at SVB LeerinkForma Therapeutics (NASDAQ:FMTX) Price Target Cut to $54.00 by Analysts at SVB Leerink
marketbeat.com - June 11 at 1:13 PM
Forma Therapeutics (FMTX) & Its Competitors Financial ComparisonForma Therapeutics (FMTX) & Its Competitors Financial Comparison
americanbankingnews.com - June 18 at 5:12 AM
Heres Why Were Not Too Worried About Forma Therapeutics Holdings (NASDAQ:FMTX) Cash Burn SituationHere's Why We're Not Too Worried About Forma Therapeutics Holdings' (NASDAQ:FMTX) Cash Burn Situation
finance.yahoo.com - June 17 at 1:50 PM
Forma Therapeutics (NASDAQ:FMTX) versus Taysha Gene Therapies (NASDAQ:TSHA) Financial ReviewForma Therapeutics (NASDAQ:FMTX) versus Taysha Gene Therapies (NASDAQ:TSHA) Financial Review
americanbankingnews.com - June 16 at 9:16 PM
Contrasting Forma Therapeutics (FMTX) & The CompetitionContrasting Forma Therapeutics (FMTX) & The Competition
americanbankingnews.com - June 16 at 1:04 PM
Forma Therapeutics (NASDAQ:FMTX) Trading Up 4.8%Forma Therapeutics (NASDAQ:FMTX) Trading Up 4.8%
americanbankingnews.com - June 14 at 12:40 PM
Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology OfficerForma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer
finance.yahoo.com - June 14 at 7:45 AM
Forma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell DiseaseForma Therapeutics Stock Drops After Disappointing EHA Presentation For Etavopivat In Sickle Cell Disease
finance.yahoo.com - June 11 at 7:36 PM
SVB Leerink Trims Forma Therapeutics (NASDAQ:FMTX) Target Price to $54.00SVB Leerink Trims Forma Therapeutics (NASDAQ:FMTX) Target Price to $54.00
americanbankingnews.com - June 11 at 1:54 PM
Forma Therapeutics (NASDAQ:FMTX) Shares Gap Down to $28.05Forma Therapeutics (NASDAQ:FMTX) Shares Gap Down to $28.05
americanbankingnews.com - June 11 at 10:26 AM
Forma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association CongressForma Therapeutics Presents New Phase 1 Data on Etavopivat (formerly referred to as FT-4202) at 26th European Hematology Association Congress
finance.yahoo.com - June 11 at 8:32 AM
Financial Contrast: Forma Therapeutics (FMTX) vs. The CompetitionFinancial Contrast: Forma Therapeutics (FMTX) vs. The Competition
americanbankingnews.com - June 10 at 7:14 AM
Forma Therapeutics (FMTX) versus Its Competitors Financial ReviewForma Therapeutics (FMTX) versus Its Competitors Financial Review
americanbankingnews.com - June 7 at 5:16 PM
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Buy" by AnalystsForma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Buy" by Analysts
americanbankingnews.com - June 5 at 9:42 AM
Head to Head Comparison: Forma Therapeutics (FMTX) and Its PeersHead to Head Comparison: Forma Therapeutics (FMTX) and Its Peers
americanbankingnews.com - May 31 at 11:12 PM
Financial Analysis: Forma Therapeutics (NASDAQ:FMTX) versus Eiger BioPharmaceuticals (NASDAQ:EIGR)Financial Analysis: Forma Therapeutics (NASDAQ:FMTX) versus Eiger BioPharmaceuticals (NASDAQ:EIGR)
americanbankingnews.com - May 27 at 9:18 AM
Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021
finance.yahoo.com - May 20 at 8:16 AM
Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateForma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - May 14 at 9:07 AM
Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021
finance.yahoo.com - May 6 at 8:38 AM
Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the ...Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the ...
businesswire.com - March 31 at 8:21 AM
Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease StudyForma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study
finance.yahoo.com - March 30 at 3:19 PM
Forma Therapeutics Holdings Inc to Host Earnings CallForma Therapeutics Holdings Inc to Host Earnings Call
finance.yahoo.com - March 30 at 10:19 AM
Forma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus StudyForma Therapeutics Announces Positive FT-4202 600 mg Multiple Ascending Dose Cohort Data Supporting the Doses Being Evaluated in Phase 2/3 Registrational Trial, Called the Hibiscus Study
finance.yahoo.com - March 30 at 10:19 AM
Forma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business UpdateForma Therapeutics Reports Fourth Quarter and Year-end 2020 Financial Results and Provides Business Update
finance.yahoo.com - March 30 at 10:19 AM
Oversold Conditions For Forma Therapeutics Holdings (FMTX)Oversold Conditions For Forma Therapeutics Holdings (FMTX)
nasdaq.com - March 26 at 5:55 PM
Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
finance.yahoo.com - March 23 at 8:01 PM
Why Forma Therapeutics (FMTX) Might Surprise This Earnings SeasonWhy Forma Therapeutics (FMTX) Might Surprise This Earnings Season
finance.yahoo.com - March 3 at 9:28 AM
Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)Forma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC)
finance.yahoo.com - January 20 at 9:26 AM
UAB leader named to board for pharma companyUAB leader named to board for pharma company
bizjournals.com - January 11 at 4:28 PM
Forma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 MilestonesForma Therapeutics Reviews 2020 Highlights and Outlines Key 2021 Milestones
finance.yahoo.com - January 11 at 11:27 AM
Forma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of DirectorsForma Therapeutics Elects Renowned Doctor and Health Disparities Expert Selwyn M. Vickers, M.D., to Board of Directors
finance.yahoo.com - January 7 at 9:37 AM
How Much Of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Do Institutions Own?How Much Of Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Do Institutions Own?
finance.yahoo.com - December 19 at 1:24 PM
Forma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesForma Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 15 at 9:33 PM
Is FMTX A Good Stock To Buy Now?Is FMTX A Good Stock To Buy Now?
finance.yahoo.com - December 10 at 11:06 PM
Forma Therapeutics Announces Pricing of Public OfferingForma Therapeutics Announces Pricing of Public Offering
finance.yahoo.com - December 10 at 11:06 PM
Forma Therapeutics Launches Proposed Public OfferingForma Therapeutics Launches Proposed Public Offering
finance.yahoo.com - December 8 at 6:33 PM
Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD)Forma Therapeutics Presents Clinical Proof-of-Concept Data at the 62nd Annual ASH Meeting Supporting the Potential of its Novel Investigational PKR Activator, FT-4202, to Treat Sickle Cell Disease (SCD)
finance.yahoo.com - December 7 at 8:39 PM
Forma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdateForma Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 12 at 9:25 AM
Forma Therapeutics sickle cell candidate an orphan drug in EuropeForma Therapeutics' sickle cell candidate an orphan drug in Europe
seekingalpha.com - November 10 at 8:10 AM
Forma Therapeutics to Participate in Upcoming Investor ConferencesForma Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - November 4 at 9:19 AM
Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)Forma Therapeutics Announces Positive Top-line Olutasidenib Data From a Planned Interim Analysis of a Registrational Phase 2 Clinical Trial in Acute Myeloid Leukemia (AML)
finance.yahoo.com - October 26 at 7:20 AM
Forma Therapeutics Holdings Inc.Forma Therapeutics Holdings Inc.
wsj.com - October 16 at 11:58 PM
We Think Forma Therapeutics Holdings (NASDAQ:FMTX) Can Afford To Drive Business GrowthWe Think Forma Therapeutics Holdings (NASDAQ:FMTX) Can Afford To Drive Business Growth
finance.yahoo.com - September 20 at 3:11 PM
Forma Therapeutics Holdings, Inc.: Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational FunctionsForma Therapeutics Holdings, Inc.: Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions
finanznachrichten.de - September 15 at 7:25 AM
Forma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational FunctionsForma Therapeutics Appoints Two New Vice Presidents to Lead Key Organizational Functions
finance.yahoo.com - September 15 at 7:25 AM
Forma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of DirectorsForma Therapeutics Appoints Biopharma Veteran Thomas G. Wiggans to Board of Directors
finance.yahoo.com - September 9 at 8:58 AM
Forma Therapeutics Holdings IncForma Therapeutics Holdings Inc
reuters.com - August 14 at 12:32 PM
Forma Therapeutics EPS misses by $3.84Forma Therapeutics EPS misses by $3.84
seekingalpha.com - August 13 at 7:59 AM
Forma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdateForma Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - August 13 at 7:59 AM
Forma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of DirectorsForma Therapeutics Elects Distinguished Researcher and Physician Wayne A.I. Frederick, M.D., to Board of Directors
finance.yahoo.com - August 5 at 5:13 PM
This page was last updated on 6/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.